Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma

NCT02786641 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

235

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Docetaxel
DRUG: Cisplatin 1
DRUG: Xeloda
RADIATION: IMRT
DRUG: Cisplatin 2

Sponsor

Sun Yat-sen University